Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00327236 · ClinicalTrials.gov registry record
The Study of Immune Cell (T Cell) Activity in Patients With Paraneoplastic Neurologic Syndromes
A clinical trial, sponsored by Rockefeller University.
- Completed
- Registry status
- 109
- Enrollment target
NCT00327236: Completed study, sponsored by Rockefeller University.
NCT00327236 is a clinical trial that has completed, run by Rockefeller University. The registered enrollment target is 109 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00327236 has completed, sponsored by Rockefeller University.
- COMPLETED
- Registry status
- 109 participants
- Enrollment target
Study Summary
The investigators believe that T cells, cells that are a part of the immune system, are what are causing the neurological problems while also attacking tumor cells. This protocol studies the clinical status of patients with paraneoplastic neurological disorder (PND) as well as their blood to understand the relationship between their neurological disease, their cancer, and their immune system.
Primary Outcome
ELISPOT
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 109 participants |
| Start Date | 1995-01 |
| Est. Completion | 2018-02 |
What the finished NCT00327236 record still lists
NCT00327236 is an observational study that tracks outcomes without assigning an intervention. The registered 109 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT00327236 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00327236 about?
NCT00327236 is a clinical study titled "The Study of Immune Cell (T Cell) Activity in Patients With Paraneoplastic Neurologic Syndromes". The investigators believe that T cells, cells that are a part of the immune system, are what are causing the neurological problems while also attacking tumor cells. This protocol studies the clinical status of patients with paraneoplastic neurological disorder (PND) as well as their blood to underst...
What is the current status of trial NCT00327236?
This trial is currently completed. The enrollment target is 109 participants. The study started on 1995-01. Estimated completion is 2018-02.
Who is sponsoring clinical trial NCT00327236?
This trial is sponsored by Rockefeller University, which has 117 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02421380 · 109 participants · NA
Characterization of Hyperpolarized Pyruvate MRI Reproducibility
- NCT04526600 · 109 participants · NA
Fidgeting and Attentional and Emotional Regulation in ADHD
- NCT04835584 · 109 participants · Phase 1
KRT-232 and TKI Study in Chronic Myeloid Leukemia
- NCT06626516 · 109 participants · Phase 1
Tebentafusp-tebn With LDT in Metastatic UM
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia